Description

ISTAMET 50/500 MG

Indications

ISTAMET 50/500 MG is primarily indicated for the management of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to improve glycemic control in patients whose blood glucose levels are not adequately controlled by diet and exercise alone. ISTAMET combines two active ingredients: sitagliptin and metformin, which work synergistically to enhance glycemic control.

Mechanism of Action

ISTAMET’s efficacy in managing blood glucose levels is attributed to its dual mechanism of action. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which in turn stimulate insulin secretion from the pancreatic beta cells in a glucose-dependent manner. This action helps to lower blood glucose levels postprandially.

Metformin, on the other hand, primarily works by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues. It enhances glucose uptake by muscles and fat tissues, thereby reducing blood glucose levels. The combination of these two mechanisms provides a comprehensive approach to managing diabetes.

Pharmacological Properties

ISTAMET is characterized by its pharmacokinetic properties, which include absorption, distribution, metabolism, and excretion. Sitagliptin is rapidly absorbed after oral administration, reaching its peak plasma concentration within 1-4 hours. It exhibits a half-life of approximately 12.4 hours, allowing for once-daily dosing.

Metformin is also well-absorbed, with peak plasma concentrations occurring approximately 2.5 hours post-administration. It has a half-life of about 6.2 hours and is primarily excreted unchanged in the urine. The pharmacokinetic profiles of both components support their effective use in managing blood glucose levels throughout the day.

Contraindications

ISTAMET is contraindicated in patients with a known hypersensitivity to sitagliptin, metformin, or any of the excipients in the formulation. It should not be used in individuals with severe renal impairment (eGFR < 30 mL/min), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with a history of lactic acidosis associated with metformin use.

Additionally, ISTAMET is not recommended for use during pregnancy or breastfeeding unless the potential benefits outweigh the risks. Patients with a history of pancreatitis should also be cautious, as there is a potential risk associated with DPP-4 inhibitors.

Side Effects

Common side effects associated with ISTAMET include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. These effects are often transient and may subside with continued use of the medication.

Serious side effects, although rare, may include lactic acidosis, pancreatitis, and hypersensitivity reactions. Symptoms of lactic acidosis include muscle pain, difficulty breathing, abdominal discomfort, and unusual fatigue. Patients should be advised to seek immediate medical attention if they experience any of these symptoms.

Dosage and Administration

The recommended starting dose of ISTAMET is typically 50 mg of sitagliptin and 500 mg of metformin, taken orally once daily. Depending on the patient’s glycemic control and tolerance, the dosage may be adjusted. The maximum recommended dose is 100 mg of sitagliptin and 2000 mg of metformin per day.

ISTAMET should be taken with meals to reduce the risk of gastrointestinal side effects and to enhance the medication’s absorption. It is essential for patients to adhere to their prescribed dosage and to consult their healthcare provider before making any changes to their treatment regimen.

Interactions

ISTAMET may interact with other medications, which could affect its efficacy or increase the risk of adverse effects. Notably, concomitant use of insulin or insulin secretagogues may increase the risk of hypoglycemia. Therefore, careful monitoring of blood glucose levels is recommended when these medications are used together.

Additionally, certain medications that affect renal function, such as diuretics or nonsteroidal anti-inflammatory drugs (NSAIDs), may increase the risk of lactic acidosis in patients taking metformin. It is crucial for healthcare providers to review all medications a patient is taking to avoid potential interactions.

Precautions

Patients taking ISTAMET should be monitored regularly for renal function, particularly those with pre-existing renal impairment or those at risk for developing renal issues. It is recommended to perform renal function tests before initiating treatment and periodically thereafter.

Patients should also be informed about the signs and symptoms of lactic acidosis and pancreatitis, as timely recognition and intervention can prevent serious complications. Lifestyle modifications, including diet and exercise, should be emphasized as part of the overall management plan for diabetes.

Clinical Studies

Clinical studies have demonstrated the efficacy of ISTAMET in improving glycemic control in patients with type 2 diabetes. In a randomized controlled trial, patients treated with ISTAMET showed significant reductions in HbA1c levels compared to those receiving metformin alone. The combination therapy was well tolerated, with a safety profile consistent with that of the individual components.

Additional studies have indicated that ISTAMET not only improves glycemic control but also has beneficial effects on weight management and cardiovascular risk factors, making it a suitable option for many patients with type 2 diabetes.

Conclusion

ISTAMET 50/500 MG is a valuable therapeutic option for the management of type 2 diabetes mellitus. By combining the actions of sitagliptin and metformin, it provides a comprehensive approach to glycemic control. While it is generally well tolerated, healthcare providers must be vigilant about potential side effects and interactions. Regular monitoring of renal function and patient education about the medication’s use are essential to ensure optimal outcomes.